tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cytomegalovirus Retinitis D017726 2 associated lipids
Telangiectasis D013684 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Vitiligo D014820 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Hemophilia B D002836 3 associated lipids
Meningococcal Infections D008589 3 associated lipids
Pouchitis D019449 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Pemphigus D010392 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Pterygium D011625 3 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Intestinal Atresia D007409 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Hyperkalemia D006947 3 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Hematologic Diseases D006402 3 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Anus Diseases D001004 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Castleman Disease D005871 3 associated lipids
Scleritis D015423 3 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Ileus D045823 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Pityriasis D010915 3 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Legionellosis D007876 3 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Toxocariasis D014120 3 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Lichen Planus D008010 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Impetigo D007169 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Trichomonas Infections D014245 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Gingivitis D005891 3 associated lipids
Ovarian Cysts D010048 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Confusion D003221 4 associated lipids
Parotitis D010309 4 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Bone Diseases D001847 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Eczema D004485 4 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Neuritis D009443 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Dermatitis, Perioral D019557 4 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Headache D006261 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Fryer JP et al. Bacterial translocation in a large-animal model of small-bowel transplantation. Portal vs systemic venous drainage and the effect of tacrolimus immunosuppression. 1996 Arch Surg pmid:8546583
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Millis JM et al. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. 1996 Transplant. Proc. pmid:8623213
Washburn WK et al. Tacrolimus rescue therapy for renal allograft rejection refractory to cyclosporine-based immunosuppression. 1996 Transplant. Proc. pmid:8623214
Delaney CP et al. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. 1996 J. Clin. Invest. pmid:8550837
Regazzi MB et al. Interaction between FK 506 and diltiazem in an animal model. 1996 Transplant. Proc. pmid:8623215
Hashikura Y et al. Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation. 1996 Transplant. Proc. pmid:8623218
Tomikawa S et al. Immunosuppressive effects of bactobolamine in vitro and in vivo. 1996 Transplant. Proc. pmid:8623223
Nakajima H and Oka T The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506. 1996 Transplant. Proc. pmid:8623224
Ko S et al. Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation. 1996 Transplant. Proc. pmid:8623229
Klintmalm GB Clinical use of FK 506 in liver transplantation. 1996 Transplant. Proc. pmid:8623484
Butt TR et al. Molecular basis of immunosuppressive drug action: regulation of steroid receptor-mediated transcription by FK 506. 1996 Transplant. Proc. pmid:8623486
Troppmann C et al. Perioperative immunosuppression as a critical determinant of early outcome after discordant xenoislet transplantation: a comparative study. 1996 Transplant. Proc. pmid:8623487
McKenna BA et al. Tacrolimus (FK 506): a whole blood assay as measured on the Abbott IMx analyzer. 1996 Transplant. Proc. pmid:8623491
Stratta RJ et al. FK 506 induction and rescue therapy in pancreas transplant recipients. 1996 Transplant. Proc. pmid:8623492
Birk PE et al. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. 1996 Transplant. Proc. pmid:8623493
Mori A et al. Enhanced production and gene expression of IL-5 in bronchial asthma. Possible management of atopic diseases with IL-5 specific gene transcription inhibitor. 1996 Adv. Exp. Med. Biol. pmid:9095279
Murao K et al. Immunosuppressant agent FK506 stimulates growth hormone (GH) secretion and gene expression of hypothalamic GH-releasing hormone in the rat. 1996 Endocrinology pmid:8603582
Fay JW et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. 1996 Blood pmid:8605372
Greeno EW et al. Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility. 1996 Transfusion pmid:8607158
Schwarz A [Drug-induced kidney damage]. 1996 Z Arztl Fortbild (Jena) pmid:8779233
Newell KA et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. 1996 Transplantation pmid:8779685
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Craescu CT et al. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. 1996 Biochemistry pmid:8780506
Singh N and Yu VL Prophylaxis for cytomegalovirus disease after liver transplant. 1996 Clin. Infect. Dis. pmid:8783744
Sperr WR et al. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. 1996 J. Allergy Clin. Immunol. pmid:8757216
Venkataraman L et al. Differential regulation of c-Rel translocation in activated B and T cells. 1996 J. Immunol. pmid:8757620
Brunner T et al. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. 1996 Int. Immunol. pmid:8757947
Wu J et al. Reversal of multidrug resistance by tacrolimus hydrate. 1996 Methods Find Exp Clin Pharmacol pmid:9121220
Gusev AI et al. A quantitative study of in vitro hepatic metabolism of tacrolimus (FK506) using secondary ion and matrix-assisted laser desorption/ionization mass spectrometry. 1996 Rapid Commun. Mass Spectrom. pmid:8759330
Yamada T et al. Synergistic effect of FK 506 and trifluoperazine on the immunosuppression in rat small bowel transplantation. 1996 Transplant. Proc. pmid:8907927
Rossi G et al. Results of orthotopic liver-small bowel transplantation in the pig using different immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907932
Platz KP et al. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation. 1996 Transplant. Proc. pmid:8907933
Velio P et al. Rejection and survival after total orthotopic liver-small bowel allotransplantation in pigs immunosuppressed with FK 506. 1996 Transplant. Proc. pmid:8907936
Bardella MT et al. FK 506 and cyclosporine: effect on D-xylose absorption in pigs with orthotopic liver-small bowel allotransplants. 1996 Transplant. Proc. pmid:8907937
Sugitani A et al. Intestinal neurons in acute and chronic rejection after small bowel transplantation in dogs. 1996 Transplant. Proc. pmid:8907941
Ronchetti F et al. Mucosal hyaluronic acid quantification in small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907950
James DG A new immunosuppressant: tacrolimus. 1996 Postgrad Med J pmid:8977938
Weppler D et al. Status of liver and gastrointestinal transplantation at the University of Miami. 1996 Clin Transpl pmid:9286568
Cooley HM et al. Resolution of pyoderma gangrenosum using tacolimus (FK-506) 1996 Aust N Z J Med pmid:8744629
Ichinari H et al. Effects of portal venous inoculation with donor splenocytes on lung allograft survival in dogs. 1996 J. Thorac. Cardiovasc. Surg. pmid:8751494
Sunyecz JA et al. Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506. 1996 Gynecol. Oncol. pmid:8751565
Ho SN et al. Dimeric ligands define a role for transcriptional activation domains in reinitiation. 1996 Nature pmid:8752278
Motamedi H et al. Characterization of methyltransferase and hydroxylase genes involved in the biosynthesis of the immunosuppressants FK506 and FK520. 1996 J. Bacteriol. pmid:8752344
Yamashita M et al. Non-T cell-derived IL-4 plays an important role in IgE production induced by antigen resensitization and is resistant to FK506. 1996 J. Immunol. pmid:8752921
Silva ND and Prendergast FG Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations. 1996 Biophys. J. pmid:8785272
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Golling M et al. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. 1996 Transplant. Proc. pmid:8962234
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Yokoyama I et al. Decreased Fas antigen expression of cultured hepatocytes with FK 506. 1996 Transplant. Proc. pmid:8962237
Mueller AR et al. Long-term follow-up in hepatitis C patients with respect to immunosuppression. 1996 Transplant. Proc. pmid:8962255
Jonas S et al. Posttransplant malignancy and newer immunosuppressive protocols after liver transplantation. 1996 Transplant. Proc. pmid:8962257
Taylor P et al. Conformational polymorphism in peptidic and nonpeptidic drug molecules. 1996 Biopolymers pmid:9101762
Yagura K et al. Pharmacokinetic characteristics of two types of liposomal FK 506. 1996 Transplant. Proc. pmid:8658708
Ogawa N et al. Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation. 1996 Transplant. Proc. pmid:8658710
Yoshida Y et al. Effect of lipoprostaglandin E1 in concordant xenografts. 1996 Transplant. Proc. pmid:8658716
Kawauchi M et al. Which are the target vessels of xeno- and allo-lung rejection?--a primate single lung transplantation study. 1996 Transplant. Proc. pmid:8658719
Sakimoto H et al. Administration of tacrolimus (FK506) in hamster-to-rat pancreas xenotransplantation. 1996 Transplant. Proc. pmid:8658727
Takeda M et al. Pretreatment with splenectomy and FK506 in xeno-lung transplantation. 1996 Transplant. Proc. pmid:8658728
Shapiro R et al. "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. 1996 Transplantation pmid:8932264
Zou XM et al. Immunosuppressive effect of FK506 on orthotopic liver and small bowel xenotransplantation (xenoOLTx and SBTx). 1996 Transplant. Proc. pmid:8658729
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
Kokado Y et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. 1996 Transplant. Proc. pmid:8658802
Borvak J et al. The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. 1996 J. Infect. Dis. pmid:8843228
Borg AJ et al. 15-Deoxyspergualin inhibits interleukin 6 production in in vitro stimulated human lymphocytes. 1996 Transpl. Immunol. pmid:8843590
Chen BG et al. Inhibition by CsA and FK506 of the in vitro proliferative response of gamma delta T cells on stimulation with anti-TCR delta monoclonal antibody. 1996 Transpl. Immunol. pmid:8843593
Toyota N et al. Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells. 1996 Arch. Dermatol. Res. pmid:8844128
Budde K et al. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. 1996 Int J Clin Pharmacol Ther pmid:8937932
Ide T et al. An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the mongolian gerbil. 1996 Neurosci. Lett. pmid:8938254
Cai W et al. Transcription-modulating drugs: mechanism and selectivity. 1996 Curr. Opin. Biotechnol. pmid:8939643
Freiberg RA et al. Specific triggering of the Fas signal transduction pathway in normal human keratinocytes. 1996 J. Biol. Chem. pmid:8940187
Büttemeyer R et al. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. 1996 Plast. Reconstr. Surg. pmid:8532772
[Tacrolimus--a new perspective in kidney transplantation]. 1996 Urologe A pmid:9022401
Mattila PS The actions of cyclosporin A and FK506 on T-lymphocyte activation. 1996 Biochem. Soc. Trans. pmid:8674715
Adams DH and Liu Q FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients. 1996 Hepatology pmid:8675167
Halloran PF Molecular mechanisms of new immunosuppressants. 1996 Clin Transplant pmid:8680047
Luan S et al. Molecular characterization of a FKBP-type immunophilin from higher plants. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8692927
Iwasaki K et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:9029671
Bashuda H et al. Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. 1996 Transplantation pmid:8693525
Fung JJ et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. 1996 J. Am. Coll. Surg. pmid:8696542
Shaw LM et al. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. 1996 Clin. Chem. pmid:8697605
Bousvaros A et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). 1996 Gastroenterology pmid:8698205
Ezeamuzie CI Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. 1996 Int. J. Immunopharmacol. pmid:8894806
Ockenfels HM et al. The effect of cyclosporin A and FK 506 on the cAMP content in psoriatic keratinocytes. 1996 Skin Pharmacol. pmid:8896120
Nash RA et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 1996 Blood pmid:8896434
Dawson S et al. UCLA liver transplantation: analysis of immunological factors affecting outcome. 1996 Artif Organs pmid:8896726
Kashu Y et al. Prolongation of rat liver graft survival by splenectomy combined with low dose FK506 therapy. 1996 Artif Organs pmid:8896731
Ohshima S et al. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors. 1996 Artif Organs pmid:8896734
Dawson TM Immunosuppressants, immunophilins, and the nervous system. 1996 Ann. Neurol. pmid:8871573
Small SL et al. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) 1996 Ann. Neurol. pmid:8871576
Saada V et al. Comparative evaluation of in vitro and in vivo immunosuppressive potential of cyclosporin G with cyclosporin A and FK-506. 1996 Int. J. Immunopharmacol. pmid:8732436
Asante-Korang A et al. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. 1996 J. Heart Lung Transplant. pmid:8732602
Rifai N et al. The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. 1996 Clin. Biochem. pmid:8601324
Vilquin JT et al. Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation. 1996 J. Cell Biol. pmid:8601607
Schuetz EG et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. 1996 Mol. Pharmacol. pmid:8632764
Sun S et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. 1996 Transplantation pmid:8633368
Kashu Y et al. The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. 1996 Transplantation pmid:8633382
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388
Ohtomo Y et al. C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y. 1996 Diabetologia pmid:8635672